This week Probmet Therapeutics took part in the Nordic Life Science Days 🙌 Our very own Lasse Nørregaard presented our groundbreaking therapy for treating metastatic breast cancer as part of the Nordic Star Pitch Competition!! We were extremely excited to be invited for this competition and proud to share the stage with fellow BioInnovation Institute companies Loma Technology, Droplet IV, metaLead and Pephexia Therapeutics ApS 👏 It was a great program, and a great opportunity for us to connect with fellow innovators, investors and leaders in the life science industry!
Probmet Therapeutics
Forskning inden for bioteknologi
An oncology therapeutics company developing new targeted treatments for breast cancer brain metastatic patients.
Om os
Probmet is a precision oncology therapeutics company that is developing targeted treatments for breast cancer brain metastatic patients. The team will lead the development of breakthrough targeted therapies for metastatic breast cancer in the brain, a devastating disease that currently has limited treatment options.
- Websted
-
www.probmet.com
Eksternt link til Probmet Therapeutics
- Branche
- Forskning inden for bioteknologi
- Virksomhedsstørrelse
- 2-10 medarbejdere
- Hovedkvarter
- Copenhagen
- Type
- Privat
- Grundlagt
- 2022
Beliggenheder
-
Primær
Se ruten
Ole Maaløes Vej 3, 2200
Copenhagen, DK
Medarbejdere hos Probmet Therapeutics
Opdateringer
-
🎉 We have had a great start to 2024 🎉 We kicked off the year with an investment from Innovation Fund Denmark - the Innobooster. This supportive grant of 1.4M DKK will accelerate the development of our lead peptide drug for the treatment of metastatic breast cancer. 🔬 We are very grateful for this support that will enable us to conduct essential pre-clinical studies and get us one step closer to our goal of offering new treatment options to patients with metastatic breast cancer. 🎗 Stay tuned for more developments 🚀 #innobooster #funding #investment #breastcancer #metastasis #denmark BioInnovation Institute RCSI Innovation